Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
NCT ID: NCT01389609
Last Updated: 2021-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2011-07-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants
NCT03627936
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
NCT06168929
Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects
NCT01595425
Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions
NCT06823362
Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects
NCT05841446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
Doxazosin 4 mg Japanese marketed IR tablet
Immediate release tablet, 4 mg, single dose
B
Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
Doxazosin 4 mg ODT with water
Orally-disintegrating Tablet , 4 mg, single dose with water
C
Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
Doxazosin 4 mg ODT without water
Orally-disintegrating Tablet , 4 mg, single dose without water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxazosin 4 mg Japanese marketed IR tablet
Immediate release tablet, 4 mg, single dose
Doxazosin 4 mg ODT with water
Orally-disintegrating Tablet , 4 mg, single dose with water
Doxazosin 4 mg ODT without water
Orally-disintegrating Tablet , 4 mg, single dose without water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Shinjuku-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0351069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.